Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of organ confined prostate cancer.

Further Study Information

This is a single site, non-randomized, prospective, phase IV trial of patients with organ-confined prostate cancer. Data collected will include patient demographics, pathology data, tumor stage, SBRT dose fractionation scheme, dose received by adjacent critical normal tissues,tumor recurrence data, and acute and late toxicities. Follow up data will be collected during the patient's standard office visits. The anticipated duration of this study is 5 years.

Eligibility Criteria

Inclusion Criteria:

• Patient age >= 18 years

• Zubrod performance status of 0-3

• T1-3 N0 M0 adenocarcinoma of the prostate

• Prostate volume ≤ 100 cc

• Signed study-specific consent form

Exclusion Criteria

• Extension of local tumor to involve adjacent organs other than seminal vesicles (T4)

• Prostate volume > 100 cc

• Nodal involvement

• Metastatic disease

• Prior pelvic radiotherapy except as part of combination therapy for prostate cancer

• History of scleroderma

• Patients with psychiatric or addictive disorder that would preclude obtaining informed consent

Trial Contact Information

Trial Lead Organizations/Sponsors

David C. Pratt Cancer Center at St. John's Mercy

Jaymeson Stroud, MD		Ph: 314-251-6844
		Email: jaymeson.stroud@mercy.net

U.S.A.
Missouri
	St. Louis
	David C. Pratt Cancer Center at St. John's Mercy

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01352598
Information obtained from ClinicalTrials.gov on November 20, 2012

Back to Top